Sunday, November 8, 2026

USD/EUR Is 1% Down In The Last 21 Sessions

USD/EUR Is 1% Down In The Last 21 Sessions

(VIANEWS) - USD/EUR (USDEUR) has been up by 1.99% for the last 21 sessions. At 01:07 EST on Thursday, 22 June, USD/EUR (USDEUR) is $0.91.

USD/EUR's yearly highs and lows, it's 0.954% up from its 52-week low and 13.185% down from its 52-week high.

Volatility

USD/EUR's last week, last month's, and last quarter's current intraday variation average was a negative 0.51%, a negative 0.09%, and a positive 0.37%, respectively.

USD/EUR's highest amplitude of average volatility was 0.61% (last week), 0.32% (last month), and 0.37% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, USD/EUR's Forex is considered to be overbought (>=80).

News about

  • Usd/jpy eases after refreshing yearly top above 142.00 as yields dribble amid full markets. According to FXStreet on Tuesday, 20 June, "However, the People's Bank of China's (PBoC) rate cut and Japan Finance Minister (FinMin) Shunichi Suzuki's comments appear to prod the market sentiment, US Treasury bond yields and the USD/JPY prices of late.", "Moving on, USD/JPY is likely to remain firmer but the second-tier US housing data, Japan Industrial Production for April and Fed versus BoJ updates will be the key to watch for the clear directions."
  • Usd/jpy consolidates around 142.00 mark, just below YTD high set this Tuesday. According to FXStreet on Tuesday, 20 June, "This, in turn, triggers a fresh leg up in the US Treasury bond yields, which allows the USD to capitalize on its recent recovery from over a one-month low touched last Friday and further acts as a tailwind for the USD/JPY pair. ", "The USD/JPY pair reverses an intraday dip and trades around the 142.00 mark during the early European session, just below its highest level since November 2022 touched earlier this Tuesday."
  • Usd/jpy technical analysis: overbought levels - 20 June 2023. According to DailyForex on Tuesday, 20 June, "For three consecutive trading sessions, the price of the USD/JPY currency pair stabilized around its recent strong gains. ", "Forecasts of the US dollar against the Japanese yen today:The general trend of the USD/JPY currency pair is still bullish."
  • Usd/jpy: FX intervention unlikely until 145 – socgen. According to FXStreet on Tuesday, 20 June, "A further widening of UST/JGB differentials in the run-up to the July meeting and acceleration of USD/JPY beyond 145 could see the return of FX intervention."
  • Usd/jpy price analysis: bears eye a run to test 141 the figure. According to FXStreet on Tuesday, 20 June, "USTreasury yields also eased but USD/JPY fell to 141.21 from a high of 142.25 nonetheless. "

More news about USD/EUR (USDEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com